181 related articles for article (PubMed ID: 22457278)
1. Association of polymorphisms of the mu opioid receptor gene with the severity of HIV infection and response to HIV treatment.
Proudnikov D; Randesi M; Levran O; Crystal H; Dorn M; Ott J; Ho A; Kreek MJ
J Infect Dis; 2012 Jun; 205(11):1745-56. PubMed ID: 22457278
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms of the kappa opioid receptor and prodynorphin genes: HIV risk and HIV natural history.
Proudnikov D; Randesi M; Levran O; Yuferov V; Crystal H; Ho A; Ott J; Kreek MJ
J Acquir Immune Defic Syndr; 2013 May; 63(1):17-26. PubMed ID: 23392455
[TBL] [Abstract][Full Text] [Related]
3. Ethnicity interacts with the OPRM1 gene in experimental pain sensitivity.
Hastie BA; Riley JL; Kaplan L; Herrera DG; Campbell CM; Virtusio K; Mogil JS; Wallace MR; Fillingim RB
Pain; 2012 Aug; 153(8):1610-1619. PubMed ID: 22717102
[TBL] [Abstract][Full Text] [Related]
4. Short-term garlic supplementation and highly active antiretroviral treatment adherence, CD4+ cell counts, and human immunodeficiency virus viral load.
Liu C; Wang C; Robison E; Levine AM; Gandhi M; Schwartz R; Weber KM; Merenstein D
Altern Ther Health Med; 2012; 18(1):18-22. PubMed ID: 22516847
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy.
Ylitalo N; Brogly S; Hughes MD; Nachman S; Dankner W; Van Dyke R; Seage GR;
Arch Pediatr Adolesc Med; 2006 Aug; 160(8):778-87. PubMed ID: 16894075
[TBL] [Abstract][Full Text] [Related]
6. RYR3 gene variants in subclinical atherosclerosis among HIV-infected women in the Women's Interagency HIV Study (WIHS).
Shendre A; Irvin MR; Aouizerat BE; Wiener HW; Vazquez AI; Anastos K; Lazar J; Liu C; Karim R; Limdi NA; Cohen MH; Golub ET; Zhi D; Kaplan RC; Shrestha S
Atherosclerosis; 2014 Apr; 233(2):666-672. PubMed ID: 24561552
[TBL] [Abstract][Full Text] [Related]
7. CYP1A1 genotype modifies the impact of smoking on effectiveness of HAART among women.
Feldman DN; Feldman JG; Greenblatt R; Anastos K; Pearce L; Cohen M; Gange S; Leanza S; Burk R
AIDS Educ Prev; 2009 Jun; 21(3 Suppl):81-93. PubMed ID: 19537956
[TBL] [Abstract][Full Text] [Related]
8. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
[TBL] [Abstract][Full Text] [Related]
9. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
[TBL] [Abstract][Full Text] [Related]
10. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
11. Functional mu opioid receptor polymorphism (OPRM1 A(118) G) associated with heroin use outcomes in Caucasian males: A pilot study.
Woodcock EA; Lundahl LH; Burmeister M; Greenwald MK
Am J Addict; 2015 Jun; 24(4):329-35. PubMed ID: 25911999
[TBL] [Abstract][Full Text] [Related]
12. Better CD4+ T cell recovery in Brazilian HIV-infected individuals under HAART due to cumulative carriage of SDF-1-3'A, CCR2-V64I, CCR5-D32 and CCR5-promoter 59029A/G polymorphisms.
Rigato PO; Hong MA; Casseb J; Ueda M; de Castro I; Benard G; Duarte AJ
Curr HIV Res; 2008 Sep; 6(5):466-73. PubMed ID: 18855658
[TBL] [Abstract][Full Text] [Related]
13. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
[TBL] [Abstract][Full Text] [Related]
14. An investigation of the possible interaction between the use of Vitamin C and highly active antiretroviral therapy (HAART) adherence and effectiveness in treated HIV+ women.
Merenstein D; Wang C; Gandhi M; Robison E; Levine AM; Schwartz RM; Weber KM; Liu C
Complement Ther Med; 2012 Aug; 20(4):222-7. PubMed ID: 22579434
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms of Cx(3)CR1 and CXCR6 receptors in relation to HAART therapy of HIV type 1 patients.
Passam AM; Sourvinos G; Krambovitis E; Miyakis S; Stavrianeas N; Zagoreos I; Spandidos DA
AIDS Res Hum Retroviruses; 2007 Aug; 23(8):1026-32. PubMed ID: 17725420
[TBL] [Abstract][Full Text] [Related]
16. Viral load predicts new world health organization stage 3 and 4 events in HIV-infected children receiving highly active antiretroviral therapy, independent of CD4 T lymphocyte value.
Oliveira R; Krauss M; Essama-Bibi S; Hofer C; Robert Harris D; Tiraboschi A; de Souza R; Marques H; Succi R; Abreu T; Della Negra M; Hazra R; Mofenson LM; Siberry GK;
Clin Infect Dis; 2010 Dec; 51(11):1325-33. PubMed ID: 21039218
[TBL] [Abstract][Full Text] [Related]
17. Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy.
Geretti AM; Harrison L; Green H; Sabin C; Hill T; Fearnhill E; Pillay D; Dunn D;
Clin Infect Dis; 2009 May; 48(9):1296-305. PubMed ID: 19331585
[TBL] [Abstract][Full Text] [Related]
18. Association of CD209L tandem repeats polymorphism with susceptibility to human immunodeficiency virus-1 infection, disease progression, and treatment outcomes: a Moroccan cohort study.
Fayssel N; Bensghir R; Ouladlahsen A; Abdelghaffar H; Sodqi M; Lahlou K; Benjelloun S; Marhoum El Filali K; Ezzikouri S; Wakrim L
Clin Microbiol Infect; 2015 May; 21(5):513.e1-5. PubMed ID: 25656622
[TBL] [Abstract][Full Text] [Related]
19. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
20. Association of Y chromosome haplogroup I with HIV progression, and HAART outcome.
Sezgin E; Lind JM; Shrestha S; Hendrickson S; Goedert JJ; Donfield S; Kirk GD; Phair JP; Troyer JL; O'Brien SJ; Smith MW
Hum Genet; 2009 Apr; 125(3):281-94. PubMed ID: 19169712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
